加齢や高血糖によって発生して病変を誘発する化合物群

終末糖化産物、最終糖化産物、最終糖化反応物

関: advanced glycation endproduct、advanced glycosylation end product、AGE

WordNet

put an end to; "The terrible news ended our hopes that he had survived"
a final state; "he came to a bad end"; "the so-called glorious experiment came to an inglorious end" (同)destruction, death
the point in time at which something ends; "the end of the year"; "the ending of warranty period" (同)ending
bring to an end or halt; "She ended their friendship when she found out that he had once been convicted of a crime"; "The attack on Poland terminated the relatively peaceful period after WW I" (同)terminate
a piece of cloth that is left over after the rest has been used or sold (同)remainder, remnant, oddment
(American football) a position on the line of scrimmage; "no one wanted to play end"
the part you are expected to play; "he held up his end"
the concluding parts of an event or occurrence; "the end was exciting"; "I had to miss the last of the movie" (同)last, final_stage
either extremity of something that has length; "the end of the pier"; "she knotted the end of the thread"; "they rode to the end of the line"; "the terminals of the anterior arches of the fornix" (同)terminal
(football) the person who plays at one end of the line of scrimmage; "the end managed to hold onto the pass"
a boundary marking the extremities of something; "the end of town"
a final part or section; "we have given it at the end of the section since it involves the calculus"; "Start at the beginning and go on until you come to the end"
one of two places from which people are communicating to each other; "the phone rang at the other end"; "both ends wrote at the same time"
the surface at either extremity of a three-dimensional object; "one end of the box was marked `This side up"
have an end, in a temporal, spatial, or quantitative sense; either spatial or metaphorical; "the bronchioles terminate in a capillary bed"; "Your rights stop where you infringe upon the rights of other"; "My property ends by the bushes"; "The symphony ends in a pianissimo" (同)stop, finish, terminate, cease
be the end of; be the last or concluding part of; "This sad scene ended the movie" (同)terminate
increase in price or value; "the news caused a general advance on the stock market" (同)rise
an amount paid before it is earned (同)cash advance
rise in rate or price; "The stock market gained 24 points today" (同)gain
pay in advance; "Can you advance me some money?"
situated ahead or going before; "an advance party"; "at that time the most advanced outpost was still east of the Rockies" (同)advanced, in advance
being ahead of time or need; "gave advance warning"; "was beforehand with her report" (同)beforehand
cause to move forward; "Can you move the car seat forward?" (同)bring forward
move forward, also in the metaphorical sense; "Time marches on" (同)progress, pass_on, move on, march on, go_on
move forward; "we have to advance clocks and watches when we travel eastward" (同)set ahead
bring forward for consideration or acceptance; "advance an argument" (同)throw out
develop further; "We are advancing technology every day"
farther along in physical or mental development; "the childs skeletal age was classified as `advanced"; "children in the advanced classes in elementary school read far above grade average"
ahead of the times; "the advanced teaching methods"; "had advanced views on the subject"; "a forward-looking corporation"; "is British industry innovative enough?" (同)forward-looking, innovative, modern
far along in time; "a man of advanced age"; "advanced in years"; "a ripe old age"; "the ripe age of 90" (同)ripe
ahead in development; complex or intricate; "advanced technology"; "a sophisticated electronic control system" (同)sophisticated
(of societies) highly developed especially in technology or industry; "advanced societies"; "an advanced country technologically"
at a higher level in training or knowledge or skill; "an advanced degree"; "an advanced text in physics"; "special seminars for small groups of advanced students at the University"
comparatively late in a course of development; "the illness had reached an advanced stage"; "an advanced state of exhaustion"
a chemical substance formed as a result of a chemical reaction; "a product of lime and nitric acid"
a consequence of someones efforts or of a particular set of circumstances; "skill is the product of hours of practice"; "his reaction was the product of hunger and fatigue"
an artifact that has been created by someone or some process; "they improve their product every year"; "they export most of their agricultural production" (同)production
a quantity obtained by multiplication; "the product of 2 and 3 is 6" (同)mathematical product
event whose occurrence ends something; "his death marked the ending of an era"; "when these final episodes are broadcast it will be the finish of the show" (同)conclusion, finish
the end of a word (a suffix or inflectional ending or final morpheme); "I dont like words that have -ism as an ending" (同)termination

PrepTutorEJDIC

(細いものの)『端』,先端《+『of』+『名』》 / (物語などの)『終り』,終結部《+『of』+『名』》 / (物事・期間の)『最後』《+『of』+『名』》;(…に)結末をつけるもの《+『to』+『名』》 / (…の)端の部分,末端部《『of』+『名』》 / 《しばしば複数形で》『目的』(purpose),目標(aim) / 《遠回しに》死,滅亡 / 《しばしば複数形で》切れ端,くず,残りもの / (事業などの)部門(part) / (フットボールで)エンド)前衛両端の選手または位置) / …‘を'『終わらせる』,終える / 〈物事が〉…‘の'終りとなる,‘を'締めくくる / 『終わる』,終了する(come to an end)
…'を'『前進させる』,前に出す / 〈事〉'を'『進める』,促進する / (ある階級・地位などに)〈人〉'を'昇進させる《+『名』〈人〉+『to』+『名』》 / 《『advance』+『名』〈人〉+『名』〈金〉=『advance』+『名』〈金〉+『to』+『名』〈人〉》〈人〉‘に'〈金〉'を'前払いする,融資する / 〈時間・期日〉'を'早める;〈時計〉‘の'時間を早める / (…に向かって)『前進する』,進む《+『on』(『upon, toward』)+『名』》 / (…に)昇進する《+『to』(『in』)+『名』》 / 〈事が〉進歩する,はかどる / 〈時が〉進む / 〈値段・価値が〉上がる / 〈U〉〈C〉『進むこと』,前進 / 〈U〉(…の)流れ,進行《+『of』+『名』》 / 〈U〉〈C〉(…の)進歩,発達《+『of』+『名』》 / 〈U〉〈C〉(…への)昇進,出世《+『to』+『名』》 / 〈C〉(…の)前払い,前払い金《+『on』+『名』》 / 《複数形で》(人に)言い寄ること,取り入ること《+『to』+『名』》 / 前進している / 前もっての
進出した,前進した / 進歩した / 上級の,高等の / (時が)進んだ,進行した
『産物』;製品 / (…の)結果,帰結《+『of』+『名』(do『ing』)》 / (数の)積 / (化学の)生成物
終り,終了;(物語・映画などの)結末 / (文の)語尾

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/05/27 17:09:15」(JST)

wiki en

[Wiki en表示]

Advanced glycation end products (AGEs) are proteins or lipids that become glycated as a result of exposure to sugars.^[1] They can be a factor in aging and in the development or worsening of many degenerative diseases, such as diabetes, atherosclerosis, chronic kidney disease, and Alzheimer's disease.^[2]

Effects

AGEs affect nearly every type of cell and molecule in the body and are thought to be one factor in aging and some age-related chronic diseases.^[3]^[4]^[5] They are also believed to play a causative role in the vascular complications of diabetes mellitus.^[6]

Under certain pathologic conditions, such as oxidative stress due to hyperglycemia in patients with diabetes,^[7] and hyperlipidemia,^{[citation needed]} AGE formation can be increased beyond normal levels. AGEs are now known to play a role as proinflammatory mediators in gestational diabetes as well.^[8]

The animal and human evidence is that significant amounts of dietary advanced glycation end-products (dAGEs) are absorbed, and that dAGEs contribute to the body's burden of AGE, and are associated with diseases such as atherosclerosis and kidney disease.^[9]

In the context of cardiovascular disease, AGEs can induce crosslinking of collagen which can cause vascular stiffening and entrapment of low-density lipoprotein particles (LDL) in the artery walls. AGEs can also cause glycation of LDL which can promote its oxidation.^[10] Oxidized LDL is one of the major factors in the development of atherosclerosis.^[11] Finally, AGEs can bind to RAGE (receptor for advanced glycation end products) and cause oxidative stress as well as activation of inflammatory pathways in vascular endothelial cells.^[10]^[11]

In other diseases

The formation and accumulation of advanced glycation endproducts (AGEs) has been implicated in the progression of age-related diseases.^[12] AGEs have been implicated in Alzheimer's Disease,^[13] cardiovascular disease,^[14] and stroke.^[15] The mechanism by which AGEs induce damage is through a process called cross-linking that causes intracellular damage and apoptosis.^[16] They form photosensitizers in the crystalline lens,^[17] which has implications for cataract development.^[18] Reduced muscle function is also associated with AGEs.^[19]

Pathology

AGEs have a range of pathological effects, such as:^[20]^[21]

Increased vascular permeability.
Increased arterial stiffness
Inhibition of vascular dilation by interfering with nitric oxide.
Oxidizing LDL.
Binding cells—including macrophage, endothelial, and mesangial—to induce the secretion of a variety of cytokines.
Enhanced oxidative stress.

Reactivity

Proteins are usually glycated through their lysine residues.^[22] In humans, histones in the cell nucleus are richest in lysine, and therefore form the glycated protein N(6)-Carboxymethyllysine (CML).^[22]

A receptor (biochemistry) nicknamed RAGE, from receptor for advanced glycation end products, is found on many cells, including endothelial cells, smooth muscle, cells of the immune system^[which?] from tissue such as lung, liver, and kidney.^{[clarification needed]}^[which?] This receptor, when binding AGEs, contributes to age- and diabetes-related chronic inflammatory diseases such as atherosclerosis, asthma, arthritis, myocardial infarction, nephropathy, retinopathy, periodontitis and neuropathy.^[23] The pathogenesis of this process hypothesized to activation of the nuclear factor kappa B (NF-κB) following AGE binding. NF-κB controls several genes which are involved in inflammation.^{[citation needed]}

Clearance

In clearance, or the rate at which a substance is removed or cleared from the body, it has been found that the cellular proteolysis of AGEs—the breakdown of proteins—produces AGE peptides and "AGE free adducts" (AGE adducts bound to single amino acids). These latter, after being released into the plasma, can be excreted in the urine.^[24]

1. Renal pyramid • 2. Interlobular artery • 3. Renal artery • 4. Renal vein 5. Renal hilum • 6. Renal pelvis • 7. Ureter • 8. Minor calyx • 9. Renal capsule • 10. Inferior renal capsule • 11. Superior renal capsule • 12. Interlobular vein • 13. Nephron • 14. Minor calyx • 15. Major calyx • 16. Renal papilla • 17. Renal column

Nevertheless, the resistance of extracellular matrix proteins to proteolysis renders their advanced glycation end products less conducive to being eliminated.^[24] While the AGE free adducts are released directly into the urine, AGE peptides are endocytosed by the epithelial cells of the proximal tubule and then degraded by the endolysosomal system to produce AGE amino acids. It is thought that these acids are then returned to the kidney's inside space, or lumen, for excretion. ^[20] AGE free adducts are the major form through which AGEs are excreted in urine, with AGE-peptides occurring to a lesser extent^[20] but accumulating in the plasma of patients with chronic kidney failure.^[24]

Larger, extracellularly derived AGE proteins cannot pass through the basement membrane of the renal corpuscle and must first be degraded into AGE peptides and AGE free adducts. Peripheral macrophage^[20] as well as liver sinusoidal endothelial cells and Kupffer cells ^[25] have been implicated in this process, although the real-life involvement of the liver has been disputed. ^[26]

Endothelial cell

Large AGE proteins unable to enter the Bowman's capsule are capable of binding to receptors on endothelial and mesangial cells and to the mesangial matrix.^[20] Activation of RAGE induces production of a variety of cytokines, including TNFβ, which mediates an inhibition of metalloproteinase and increases production of mesangial matrix, leading to glomerulosclerosis^[21] and decreasing kidney function in patients with unusually high AGE levels.

Although the only form suitable for urinary excretion, the breakdown products of AGE—that is, peptides and free adducts—are more aggressive than the AGE proteins from which they are derived, and they can perpetuate related pathology in diabetic patients, even after hyperglycemia has been brought under control.^[20]

Some AGEs have an innate catalytic oxidative capacity, while activation of NAD(P)H oxidase through activation of RAGE and damage to mitochondrial proteins leading to mitochondrial dysfunction can also induce oxidative stress. Because perpetuation can result through AGEs' oxidative effects, concurrent treatment with antioxidants might help halt the cycle.^[21] In the end, effective clearance is necessary, and those suffering AGE increases because of kidney dysfunction might require a kidney transplant.^[20]

In diabetics who have an increased production of an AGE, kidney damage reduces the subsequent urinary removal of AGEs, forming a positive feedback loop that increases the rate of damage. A 1997 study concluded that adding sugar to egg whites causes diabetics to be 200 times more AGE immunoreactive.^{[clarification needed]}^[27]

Potential therapy

Diagram of a resveratrol molecule

AGEs are the subject of ongoing research. There are three therapeutic approaches: preventing the formation of AGEs, breaking crosslinks after they are formed and preventing their negative effects.

Compounds that have been found to inhibit AGE formation in the laboratory include Vitamin C, benfotiamine, pyridoxamine, alpha-lipoic acid,^[28] taurine,^[29] pimagedine,^[30] aspirin,^[31]^[32] carnosine,^[33] metformin,^[34] pioglitazone,^[34] and pentoxifylline.^[34]

Studies in rats and mice have found that natural phenols such as resveratrol and curcumin can prevent the negative effects of the AGEs.^[35]^[36]

Compounds that are thought to break some existing AGE crosslinks include Alagebrium (and related ALT-462, ALT-486, and ALT-946)^[37] and N-phenacyl thiazolium bromide.^[38] One in vitro study shows that rosmarinic acid out performs the AGE breaking potential of ALT-711.^[39]

Diagram of a glucosepane molecule

There is, however, no agent known that can break down the most common AGE, glucosepane, which appears 10 to 1,000 times more common in human tissue than any other cross-linking AGE.^[40]^[41]

Some chemicals, on the other hand, like aminoguanidine, might limit the formation of AGEs by reacting with 3-deoxyglucosone.^[23]

References

^ "American Heart Association". Retrieved 5 May 2016.
^ Vistoli, G; De Maddis, D; Cipak, A; Zarkovic, N; Carini, M; Aldini, G (Aug 2013). "Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation.". Free Radic Res. 47: Suppl 1:3–27. doi:10.3109/10715762.2013.815348. PMID 23767955.
^ Glenn, J.; Stitt, A. (2009). "The role of advanced glycation end products in retinal ageing and disease". Biochimica et Biophysica Acta. 1790 (10): 1109–1116. doi:10.1016/j.bbagen.2009.04.016. PMID 19409449.
^ Semba, R. D.; Ferrucci, L.; Sun, K.; Beck, J.; Dalal, M.; Varadhan, R.; Walston, J.; Guralnik, J. M.; Fried, L. P. (2009). "Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women". Aging clinical and experimental research. 21 (2): 182–190. doi:10.1007/BF03325227. PMC 2684987 . PMID 19448391.
^ Semba, R.; Najjar, S.; Sun, K.; Lakatta, E.; Ferrucci, L. (2009). "Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults". American Journal of Hypertension. 22 (1): 74–79. doi:10.1038/ajh.2008.320. PMC 2637811 . PMID 19023277.
^ Yan, S. F.; D'Agati, V.; Schmidt, A. M.; Ramasamy, R. (2007). "Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging". Current molecular medicine. 7 (8): 699–710. doi:10.2174/156652407783220732. PMID 18331228.
^ Brownlee, M (June 2005). "The pathobiology of diabetic complications: a unifying mechanism.". Diabetes. 54 (6): 1615–25. doi:10.2337/diabetes.54.6.1615. PMID 15919781.
^ Pertyńska-Marczewska, M; Głowacka, E; Sobczak, M; Cypryk, K; Wilczyński, J (February 2009). "Glycation endproducts, soluble receptor for advanced glycation endproducts and cytokines in diabetic and non-diabetic pregnancies.". American journal of reproductive immunology (New York, N.Y. : 1989). 61 (2): 175–82. doi:10.1111/j.1600-0897.2008.00679.x. PMID 19143681.
^ Uribarri, J; Woodruff, S; Goodman, S; Cai, W; Chen, X; Pyzik, R; Yong, A; Striker, GE; Vlassara, H (June 2010). "Advanced glycation end products in foods and a practical guide to their reduction in the diet". Journal of the American Dietetic Association. 110 (6): 911–16.e12. doi:10.1016/j.jada.2010.03.018. PMC 3704564 . PMID 20497781.
^ ^a ^b Prasad, Anand; Bekker, Peter; Tsimikas, Sotirios (2012-08-01). "Advanced glycation end products and diabetic cardiovascular disease". Cardiology in Review. 20 (4): 177–183. doi:10.1097/CRD.0b013e318244e57c. ISSN 1538-4683. PMID 22314141.
^ ^a ^b Di Marco, Elyse; Gray, Stephen P.; Jandeleit-Dahm, Karin (2013-01-01). "Diabetes alters activation and repression of pro- and anti-inflammatory signaling pathways in the vasculature". Frontiers in Endocrinology. 4: 68. doi:10.3389/fendo.2013.00068. ISSN 1664-2392. PMC 3672854 . PMID 23761786.
^ Tan, KC; Chow, WS; Lam, JC; Lam, B; Bucala, R; Betteridge, J; Ip, MS (March 2006). "Advanced glycation endproducts in nondiabetic patients with obstructive sleep apnea.". Sleep. 29 (3): 329–33. PMID 16553018.
^ Srikanth, V; Maczurek, A; Phan, T; Steele, M; Westcott, B; Juskiw, D; Münch, G (May 2011). "Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.". Neurobiology of Aging. 32 (5): 763–77. doi:10.1016/j.neurobiolaging.2009.04.016. PMID 19464758.
^ Simm, A; Wagner, J; Gursinsky, T; Nass, N; Friedrich, I; Schinzel, R; Czeslik, E; Silber, RE; Scheubel, RJ (July 2007). "Advanced glycation endproducts: a biomarker for age as an outcome predictor after cardiac surgery?". Experimental Gerontology. 42 (7): 668–75. doi:10.1016/j.exger.2007.03.006. PMID 17482402.
^ Zimmerman GA, Meistrell M 3rd, Bloom O, Cockroft KM, Bianchi M, Risucci D, Broome J, Farmer P, Cerami A, Vlassara H, et al. Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proceedings of the National Academy of Sciences of the United States of America 1995 Apr 25;92(9):3744-8.
^ Shaikh S, Nicholson LF. Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation. J Neurosci Res. 2008 Jul;86(9):2071-82.
^ Fuentealba D, Friguet B, Silva E. Advanced glycation endproducts induce photocrosslinking and oxidation of bovine lens proteins through type-I mechanism. Photochem Photobiol. 2009 Jan-Feb;85(1):185-94.
^ Gul A, Rahman MA, Hasnain SN. Role of fructose concentration on cataractogenesis in senile diabetic and non-diabetic patients. Graefes Arch Clin Exp Ophthalmol. 2009 Jun;247(6):809-14.
^ Haus, JM; Carrithers, JA; Trappe, SW; Trappe, TA (December 2007). "Collagen, cross-linking, and advanced glycation end products in aging human skeletal muscle.". Journal of applied physiology (Bethesda, Md. : 1985). 103 (6): 2068–76. doi:10.1152/japplphysiol.00670.2007. PMID 17901242.
^ ^a ^b ^c ^d ^e ^f ^g Gugliucci A, Bendayan M (1996). "Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE peptides by renal proximal tubular cells". Diabetologia. 39 (2): 149–60. doi:10.1007/BF00403957. PMID 8635666.
^ ^a ^b ^c Yan HD, Li XZ, Xie JM, Li M (2007). "Effects of advanced glycation end products on renal fibrosis and oxidative stress in cultured NRK-49F cells". Chin. Med. J. 120 (9): 787–93. PMID 17531120.
^ ^a ^b Ansari NA, Moinuddin, Ali R (2011). "Glycated lysine residues: a marker for non-enzymatic protein glycation in age-related diseases". DISEASE MARKERS. 30 (6): 317–324. doi:10.3233/DMA-2011-0791. PMC 3825483 . PMID 21725160.
^ ^a ^b Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW (1995). "Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose". Biochemistry. 34 (11): 3702–9. doi:10.1021/bi00011a027. PMID 7893666.
^ ^a ^b ^c Gugliucci A, Mehlhaff K, Kinugasa E, et al. (2007). "Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance". Clin. Chim. Acta. 377 (1–2): 213–20. doi:10.1016/j.cca.2006.09.028. PMID 17118352.
^ Smedsrød B, Melkko J, Araki N, Sano H, Horiuchi S (1997). "Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells". Biochem. J. 322 (Pt 2): 567–73. PMC 1218227 . PMID 9065778.
^ Svistounov D, Smedsrød B (2004). "Hepatic clearance of advanced glycation end products (AGEs)—myth or truth?". J. Hepatol. 41 (6): 1038–40. doi:10.1016/j.jhep.2004.10.004. PMID 15582139.
^ Koschinsky, T; He, CJ; Mitsuhashi, T; Bucala, R; Liu, C; Buenting, C; Heitmann, K; Vlassara, H (Jun 10, 1997). "Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy.". Proceedings of the National Academy of Sciences of the United States of America. 94 (12): 6474–9. doi:10.1073/pnas.94.12.6474. PMC 21074 . PMID 9177242.
^ Abdul, HM; Butterfield, DA (Feb 1, 2007). "Involvement of PI3K/PKG/ERK1/2 signaling pathways in cortical neurons to trigger protection by cotreatment of acetyl-L-carnitine and alpha-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease.". Free radical biology & medicine. 42 (3): 371–84. doi:10.1016/j.freeradbiomed.2006.11.006. PMC 1808543 . PMID 17210450.
^ Nandhini AT, Thirunavukkarasu V, Anuradha CV (August 2005). "Taurine prevents collagen abnormalities in high fructose-fed rats" (PDF). Indian J. Med. Res. 122 (2): 171–7. PMID 16177476.
^ A. Gugliucci, "Sour Side of Sugar, A Glycation Web Page Archived July 1, 2007, at the Wayback Machine.
^ "Aspirin inhibits the formation of... preview & related info". Mendeley. doi:10.1016/j.diabres.2006.12.024. Retrieved 2013-11-13.
^ Bucala R, Cerami A (1992). "Advanced glycosylation: chemistry, biology, and implications for diabetes and aging". Adv. Pharmacol. Advances in Pharmacology. 23: 1–34. doi:10.1016/S1054-3589(08)60961-8. ISBN 9780120329236. PMID 1540533.
^ Guiotto A, Calderan A, Ruzza P, Borin G (2005). "Carnosine and carnosine-related antioxidants: a review". Current Medicinal Chemistry. 12 (20): 2293–2315. doi:10.2174/0929867054864796. PMID 16181134.
^ ^a ^b ^c Rahbar, S; Figarola, JL (2013-03-25). "Novel inhibitors of advanced glycation endproducts". Arch. Biochem. Biophys. 419 (1): 63–79. doi:10.1016/j.abb.2003.08.009. PMID 14568010.
^ Mizutani, K; Ikeda, K; Yamori, Y (Jul 21, 2000). "Resveratrol inhibits AGEs-induced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats.". Biochemical and Biophysical Research Communications. 274 (1): 61–7. doi:10.1006/bbrc.2000.3097. PMID 10903896.
^ Tang Y (May 2014). "Curcumin eliminates the effect of advanced glycation end-products (AGEs) on the divergent regulation of gene expression of receptors of AGEs by interrupting leptin signaling.". Lab Invest. 94 (5): 503–16. doi:10.1038/labinvest.2014.42. PMID 24614199.
^ "Advanced glycation end-product cross-link breakersA novel approach to cardiovascular pathologies related to the aging process". American Journal of Hypertension. 17: S23–S30. doi:10.1016/j.amjhyper.2004.08.022.
^ Vasan, S; Zhang, X; Zhang, X; Kapurniotu, A; Bernhagen, J; Teichberg, S; Basgen, J; Wagle, D; Shih, D; Terlecky, I; Bucala, R; Cerami, A; Egan, J; Ulrich, P (Jul 18, 1996). "An agent cleaving glucose-derived protein crosslinks in vitro and in vivo.". Nature. 382 (6588): 275–8. doi:10.1038/382275a0. PMID 8717046.
^ Daniel Jean; Maryse Pouligon; Claude Dalle. "Evaluation in vitro of AGE-crosslinks breaking ability of rosmarinic acid" (PDF). Glycative Stress Research.
^ Monnier, V. M., Mustata, G. T., Biemel, K. L., Reihl, O., Lederer, M. O., Zhenyu, D. et al. (2005). "Cross-linking of the extracellular matrix by the maillard reaction in aging and diabetes: An update on "a puzzle nearing resolution"". Annals of the New York Academy of Sciences. 1043: 533–544. doi:10.1196/annals.1333.061. PMID 16037276.
^ Furber, J.D. (2006). "Extracellular glycation crosslinks: Prospects for removal". Rejuvenation Research. Elsevier Inc. 9 (2): 274–278. doi:10.1089/rej.2006.9.274. PMID 16706655.

External links

How and Why to Prevent AGE Damage, Life Enhancement Website

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 糖尿病性腎症の概要 overview of diabetic nephropathy
2. 1型糖尿病における血糖コントロールおよび血管合併症 glycemic control and vascular complications in type 1 diabetes mellitus
3. 糖尿病性網膜症：病因 diabetic retinopathy pathogenesis
4. 糖尿病性多発性神経障害の病因および予防 pathogenesis and prevention of diabetic polyneuropathy
5. 妊娠中期の中絶：子宮内容除去術 second trimester pregnancy termination dilation and evacuation

English Journal

Angiopoietin-1 protects the endothelial cells against advanced glycation end product injury by strengthening cell junctions and inhibiting cell apoptosis.

Zhao J1, Chen L, Shu B, Tang J, Zhang L, Xie J, Liu X, Xu Y, Qi S.
Journal of cellular physiology.J Cell Physiol.2015 Aug;230(8):1895-905. doi: 10.1002/jcp.24920.
Endothelial dysfunction is a major characteristic of diabetic vasculopathy. Protection of the vascular endothelium is an essential aspect of preventing and treating diabetic vascular complications. Although Angiopoietin-1 (Ang-1) is an important endothelial-specific protective factor, whether Ang-1
PMID 25546411

Using carboxyfluorescein diacetate succinimidyl ester to monitor intracellular protein glycation.

Boucher J1, Simard É1, Froehlich U1, D'Orléans-Juste P1, Grandbois M2.
Analytical biochemistry.Anal Biochem.2015 Jun 1;478:73-81. doi: 10.1016/j.ab.2015.03.017. Epub 2015 Mar 21.
Protein glycation is a ubiquitous process involved in vascular complications observed in diabetes. Glyoxal (GO), an intracellular reactive oxoaldehyde that is one of the most potent glycation agents, readily reacts with amines present on proteins to produce the lysine-derived adduct carboxymethyllys
PMID 25800564

Proinflammatory Proteins S100A8/S100A9 Activate NK Cells via Interaction with RAGE.

Narumi K1, Miyakawa R1, Ueda R1, Hashimoto H1, Yamamoto Y1, Yoshida T2, Aoki K3.
Journal of immunology (Baltimore, Md. : 1950).J Immunol.2015 Jun 1;194(11):5539-48. doi: 10.4049/jimmunol.1402301. Epub 2015 Apr 24.
S100A8/A9, a proinflammatory protein, is upregulated in inflammatory diseases, and also has a tumor-promoting activity by the recruitment of myeloid cells and tumor cell invasion. However, whether the expression of S100A8/A9 in tumors predicts a good or poor prognosis is controversial in the clinica
PMID 25911757

Japanese Journal

Mangostanaxanthones Ⅲ and Ⅳ : advanced glycation end-product inhibitors from the pericarp of Garcinia mangostana

Journal of natural medicines 71(1), 216-226, 2017
NAID 40021062725

最新研究大豆種子エキス麹菌発酵物の抗糖化作用

Fragrance journal : Research & development for cosmetics, toiletries & allied industries = フレグランスジャーナル : 香粧品科学研究開発専門誌 44(9), 65-71, 2016-09
NAID 40020966739

New Isolinariins C, D and E, Flavonoid Glycosides from Linaria japonica

Chemical and Pharmaceutical Bulletin 64(5), 517-521, 2016
NAID 130005148738

Related Pictures

★リンクテーブル★

リンク元	「終末糖化産物」「AGE」「最終糖化産物」「advanced glycosylation end product」「最終糖化反応物」
拡張検索	「receptor for advanced glycation end products」
関連記事	「end」「advance」「product」「advanced」「glycation」